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Abstract
Population surveys for niacin deﬁciency are normally based on clinical signs or on biochemical measurements of urinary
niacin metabolites. Status may also be determined by measurement of whole blood NAD and NADP concentrations. To
compare these methods, whole blood samples and spot urine samples were collected from healthy subjects (n ¼ 2)
consuming a western diet, from patients (n ¼ 34) diagnosed with pellagra and attending a pellagra clinic in Kuito (central
Angola, where niacin deﬁciency is endemic), and from female community control subjects (n ¼ 107) who had no clinical
signs of pellagra. Whole blood NAD and NADP concentrations were measured by microtiter plate-based enzymatic assays
and the niacin urinary metabolites 1-methyl-2-pyridone-5-carboxamide (2-PYR) and 1-methylnicotinamide (1-MN) by HPLC.
Inhealthyvolunteers,inter-andintra-dayvariationsforNADandNADPconcentrationsweremuchlowerthanfortheurinary
metabolites, suggesting a more stable measure of status. However, whole blood concentrations of NAD and NADP or the
NAD:NADP ratio were not signiﬁcantly depressed in clinical pellagra. In contrast, the concentrations of 2-PYR and 1-MN,
expressed relative to either creatinine or osmolality, were lower in pellagra patients and markedly higher following treat-
ment. The use of the combined cut-offs (2-PYR ,3.0 mmol/mmol creatinine and 1-MN ,1.3 mmol/mmol creatinine) gave a
sensitivity of 91% and speciﬁcity of 72%. In conclusion, whole blood NAD and NADP concentrations gave an erroneously
lowestimateofniacindeﬁciency.Incontrast,spoturinesample2-PYRand1-MNconcentrations,relativetocreatinine,were
a sensitive and speciﬁc measure of deﬁciency. J. Nutr. 137: 2013–2017, 2007.
Introduction
Pellagra is a disease caused by a severe dietary deﬁciency in
niacin (generic name for nicotinic acid and nicotinamide) and/or
tryptophan (which is metabolized to niacin) or by an inability to
absorb and process these nutrients. Diagnosis is normally based
on clinical signs, which include a characteristic dermatitis and
changesinthegastrointestinaltractandnervous system(1).How-
ever, the correct diagnosis may be overlooked in patients where
clinical signs are atypical or absent (2,3). Although outbreaks
are now rare, sporadic cases of pellagra are reported in chronic
alcoholics and in individuals taking medication affecting tryp-
tophan metabolism, such as isoniazid therapy for tuberculosis.
In 1990 and 2000, pellagra epidemics were documented in
Malawi and central areas of Angola (4–6). In these areas, the
pellagra outbreaks were associated with a high dietary depen-
dence on unfortiﬁed maize. Given that many people in southern
and central Africa are similarly dependent on unfortiﬁed maize,
it is likely that seasonal subclinical niacin deﬁciency is wide-
spread. The accurate biochemical diagnosis of niacin status is
also of increasing interest due to its possible association with
HIV-related conditions (7) and cancer (8).
Previous studies have assessed niacin status by the quantiﬁca-
tion of the major urinary niacin metabolites 1-methylnicotinamide
(1-MN)
8 and1-methyl-2-pyridone-5-carboxamide (2-PYR), and
sometimes the more minor metabolite 1-methyl-4-pyridone-5-
carboxamide (9,10), in timed urine collections. Status is usually
expressed as the concentration ratio 2-PYR:1-MN or as the con-
centrations of the individual metabolites relative to creatinine
(10). However, it has been shown in human subjects consuming
controlled niacin diets that changes in 1-MN and 2-PYR concen-
trations, but not 2-PYR:1-MN, correlated with dietary niacin
intake, casting doubt on the utility of the ratio indicator (11,12).
In previous ﬁeld studies, timed urine collections have been
used; however, these are often not practical due to compliance
issues and the difﬁculty of relocating individuals and house-
holds. Random spot urine sampling avoids these issues and has
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Supplemental Material can be found at: been suggestedas an alternative (10,13,14). We previously showed
that in spot urine samples, the niacin metabolite ratio 2-PYR:
1-MN was highly variable due to the different excretion rates of
the 2 metabolites and was very dependent on recent dietary in-
take (15). Status was best described as the concentration of the
metabolites relative to creatinine.
An alternative method for assessing niacin status is the mea-
surement of the active coenzymes of niacin, NAD and NADP.
Erythrocyte NAD and NADP concentrations are, in principle, a
more direct measure of functional niacin status and have been
shown to respond to changes in niacin intake. In a dietary deple-
tion study, large decreases in erythrocyte NAD concentrations
were observed and these were reversed during dietary repletion
(16). Due to the relative stability of NADP concentrations, it has
been proposed that the NAD:NADP ratio may be a useful indi-
cator of niacin status (16–18).
Nicotinamide nucleotide metabolism has been investigated in
pellagra patients, consuming a staple diet of jowar (Sorghum
vulgare), in India. In contrast to the data from the dietary de-
pletion studies, this work showed no signiﬁcant change in the
concentration of NAD or NADP during clinical pellagra. How-
ever, there was evidence of impaired synthesis due to a reduction
in the activity of nicotinic acid mononucleotide adenyl transfer-
ase (19–21). This somewhat surprising ﬁnding raised important
questions about the etiology of pellagra and appropriate meth-
ods for biochemical assessment, which have not subsequently
been answered. To address these questions, we developed an
HPLC method for the analysis of the urinary niacin metabolites
1-MN and 2-PYR (15) and a modiﬁed microtiter plate method,
initially described by Jacobson and Jacobson (18), for the
enzymatic determination of whole blood NAD and NADP.
We recently reported data on the use of urinary metabolite
excretion to assess the prevalence of pellagra and niacin deﬁ-
ciencyinapellagraendemicareaofAngola(22).Here,wepresent
data on whole blood NAD and NADP in healthy control sub-
jects, subjects with clinical signs of pellagra, and patients under-
goingtreatment.WediscusstherelationshipamongNAD,NADP,
and other indicators and the implications for the biochemical
assessment of niacin status.
Subjects and Methods
Subjects. Three groups of subjects were included in this study. Two
healthy male volunteers, consuming a western-style diet, were recruited
in London for the indicative study of inter- and intra-day variability. Thirty-
four patients suffering from clinical pellagra and attending the treatment
clinic in Kuito, Central Angola, on 13 December 2004, were recruited to
the study. Cases were admitted to the clinic on the basis of an assessment
of clinical signs performed by local medical ofﬁcers. In a representative
population survey in the security cleared areas of Kuito Municipality, Bie
Province,inDecember2004, 107womenagedbetween15and49ywere
recruited to act as community control subjects.
Ethical approval. Ethical approval for the surveys was obtained from
the Angolan Ministry of Health and a letter of support issued by the
ethical review board of the Institute of Child Health, London. Individual
informed consent was obtained from all participants before samples
were taken. No material beneﬁts, other than feedback on their nutri-
tional and health situation, were offered to encourage participation.
Anthropometry and clinical signs and symptoms. Anthropometric
measurements were taken using standard equipment and methods (23).
Weight was measured to the nearest 100 g and height to the nearest
millimeter. Subjects were examined for clinical signs of niacin deﬁciency
by medically trained clinic staff. Subjects were deﬁned as suffering from
pellagra if they showed bilateral dermatitis on 1 or more sun-exposed
areas, or Casal’s necklace, or a ‘‘butterﬂy’’sign on the face. The subjects
were asked whether they had had any gastrointestinal (diarrhea) or
neurological signs of deﬁciency (headaches, depression, or insomnia) in
the previous 7 d.
Following diagnosis, patients were treated with a nicotinamide sup-
plement of 100 mg (Ucemine PP, UCB Healthcare) and a B-complex
tablet 3 times daily for 17 d. In addition, all patients received a weekly
food supplement of 400 g of a fortiﬁed blended food [corn-soy blend (6.2
mg niacin/100 g), oil, and sugar] for 3 wk. Families of pellagra patients
were also eligible for a food ration from the United Nations World
Food Program, which was distributed monthly for 3 mo. Patients were
required to return to the clinic once per week during their course of
treatment, which typically lasted for 6 wk, and at which they were given
more vitamin supplements and food rations.
Sample collection. Urine samples were collected in 100-mL disposable
cups (VWR International), transferred into 10-mL Monovette urine col-
lection tubes (VWR), and stored at 0–8 C. At the end of the day, the
urine samples were transferred into 2-mL Nalgene cryovials (VWR) and
frozen at –20 C.
Venous blood was collected using lithium heparin-coated 2-mL
Vacutainer tubes (BD) and stored in vaccine boxes at 4–8 C until the end
ofeachday. Thebloodwasthenthoroughlymixedandaliquoted (50mL)
into 2 2-mL Nalgene cryovials. The aliquots were frozen at –20 C for
up to 2 wk before being transported on dry ice from Kuito to London
via Luanda. In London, urine and whole blood samples were stored
at 280 C until analysis.
Measurement of hemoglobin (Hb) was performed using a portable
Hemocue Photometer (HemoCue), which utilizes the azidemethemoglo-
bin principle.
To measure inter- and intra-day variations in niacin metabolites,
paired fasting early morning peripheral blood and urine samples were
collected from 2 subjects on 4 consecutive days. On d 4, another 3 non-
fasting samples were collected at 3-h intervals. In total, 7 paired samples
were collected from each subject. Peripheral blood was collected from
ﬁnger pricks, made using safety lancets, into lithium heparin-coated
Microtainer tubes (BD). The samples were aliquoted (50 mL) into 2-mL
Nalgene cryovials and stored at –80 C. Urine samples were collected as
above and stored at –80 C.
Urine analysis. Urine samples were analyzed by investigators who did
not know the clinical status of the individual. The urinary niacin metab-
olites 1-MN and 2-PYR were measured by ion-pairing reverse-phase
HPLC (15). Limits of detection for 1-MN and 2-PYR were 0.4 and 0.1
mmol/L,respectively,andlimitsofquantiﬁcationwere2.6and0.5mmol/L,
respectively. A urine quality control sample (n ¼ 47, analyzed for 9 d)
following puriﬁcation and analysis had a 3.0% CV for 2-PYR (mean
concentration, 37.0 mmol/L; range, 34.8–39.4 mmol/L) and a 6.6% CV
for 1-MN (13.3 mmol/L; range, 11.6–16.0 mmol/L). Urine samples were
analyzed for creatinine (using Vitros CREA slides, Ortho-Clinical Diag-
nostics) and osmolality (using an Advanced Micro Osmometer Model
3300, Advanced Instruments) by Camelia Botna Laboratories.
Whole blood NAD and NADP concentrations. Whole blood samples
were analyzed by investigators who did not know the clinical status of
the individual. Analysis of whole blood for NAD and NADP was per-
formed using modiﬁed versions of the microtiter plate-based enzymatic
methods described by Jacobson and Jacobson (18) (the modiﬁed meth-
ods are described in detail in the online supporting material).
Limits of detection and quantiﬁcation in whole blood (assessed using
the pure standards) for NAD were 750 and 2438 nmol/L and 750 and
1875 nmol/L for NADP, respectively. Upper limits, measured using the
pure standards, were equivalent to NAD and NADP concentrations of
34,613 nmol/L and 33,413 nmol/L, respectively, in whole blood (addi-
tional details of the assay performance are given in the online supporting
material).
Statistical analysis. Means and SD are presented in the text. All
statistical tests were performed in SPSS version 13.0 (SPSS) and EpiInfo
2014 Creeke et al.
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 6.04d (CDC). Correlations were tested using the Pearson correlation test
and differences in means tested by ANOVA and Tamhane’s T2 post-hoc
test, which does not assume equal variance. Differences were considered
signiﬁcant at P , 0.05. Assessment of inter- and intra-day variation was
by percent CV. To adjust for hematocrit variations between blood sam-
ples, the Hb concentrations were measured and their relationship to
NAD and NADP concentrations described by regression formulae. The
concentrations of NAD and NADP were adjusted using the following
formulae:
AdjNAD ¼½ NAD 1ð15183ð14:1752½Hb ÞÞ:
AdjNADP ¼½ NADP 1ð12723ð14:1752½Hb ÞÞ:
The niacin index (molar ratio) was calculated as [NAD]/[NADP] 3 100.
Results
Inter- and intra-day variation in NAD, NADP, 2-PYR, and
1-MN concentrations in healthy subjects. Variations in the
concentration of NAD, NADP, 2-PYR, and 1-MN were mon-
itored over a 4-d period in paired whole blood and urine samples
in 2 healthy volunteers (Fig. 1). Inter- and intra-day variations
for NAD and NADP were much less then those for the urinary
metabolites 2-PYR and 1-MN (Table 1).
Descriptive data on patients vs. nonpatient controls. The
characteristics of the pellagra patients have been previously
described (22). Of the 34 patients recruited, 11 patients were
attending for the ﬁrst time and were classiﬁed as new untreated
cases. The other 23 had been receiving treatment for a period of
between 1 and 6 wk. The control women (n ¼ 107) showed no
clinical signs of pellagra and were aged between 15 and 49 y
(27.4 6 9.4 y). Their BMI was 21.13 6 3.25 (n ¼ 104) and their
Hb concentration 134 6 21 g/L (n ¼ 106).
Unadjusted NAD and NADP concentrations in whole blood
were paradoxically higher in pellagra patients than healthy con-
trols (Table 2). However, whole blood concentration depends on
the hematocrit of the sample and this artifact was removed when
the concentrations were expressed as the NAD:NADP ratio,
or when adjusted for the Hb concentration of the sample. The
NAD:NADP ratio did not differ between new admissions and
community controls or patients after treatment.
In contrast, the urinary concentrations of the niacin metab-
olites relative to creatinine were signiﬁcantly reduced in new
admissions compared with community controls. Concentrations
of 2-PYR were 69% lower in new admissions (P , 0.001) and
1-MN concentrations were 61% lower (P ¼ 0.002). In patients
who had commenced treatment, urinary concentrations of 2-PYR
and 1-MN were 23 times (P ¼ 0.013) and 38 times (P ¼ 0.023)
greater, respectively, than those in the control subjects.
Taking a niacin index of ,100 as a cut-off (16), whole blood
NAD and NADP concentrations classiﬁed only 36% of new ad-
missions as niacin deﬁcient. Using previously established urinary
metabolite excretion cut-offs (10) of 2-PYR ,4.0 mg/g creat-
inine (,3.0 mmol/mmol creatinine) and1-MN ,1.6 mg/g creati-
nine (,1.3 mmol/mmol creatinine), both measures individually
identiﬁed 82% of new admissions as niacin deﬁcient. However,
if the 2 urinary metabolite excretion cut-offs were used sequen-
tially, then 91% (10 of 11 patients) of new admissions were clas-
siﬁed as deﬁcient.
To assess the sensitivity andspeciﬁcityofthe biochemical mea-
sures against clinical diagnosis, data on the 11 newly admitted
pellagra patients were combined with that from the 95 control
subjects with complete datasets. Use of the urinary metabolite
cut-offs yielded a much greater sensitivity than the use of the
niacin index (Table 3). Using the combined urine metabolite cut-
offs [2-PYR ,4.0 mg/g creatinine (,3.0 mmol/mmol creatinine)
and 1-MN ,1.6 mg/g creatinine (,1.3 mmol/mmol creatinine)]
achieved the best sensitivity and reasonable speciﬁcity in iden-
tifying clinical pellagra in the study population. In comparison, a
low niacin index was an insensitive measure for the detection of
pellagra in this population.
As creatinine concentrations may be dependent on the nu-
tritional status of the subject, we investigated whether the use
of osmolality might be a more appropriate means to adjust for
urine concentration and the hydration status of the individual.
Osmolality and creatinine concentrations were correlated (r ¼
0.638; P , 0.001). However, there was no correlation between
creatinine concentration and BMI (r ¼ 20.001; P ¼ 0.990).
FIGURE 1 Variation in the concentration of whole blood NAD and
NADP concentrations (A) and niacin urinary metabolites, 1-MN and
2-PYR (B), in 2 healthy volunteers. Samples were collected over 4 d
and the results illustrate the relatively low variation in the concentra-
tions of NAD and NADP.
TABLE 1 Inter- and intra-day variations in the concentrations
of whole blood NAD and NADP and urinary 2-PYR
and 1-MN in 2 healthy male subjects
Analyte Subject 1 Subject 2 Subject 1 Subject 2
Inter-day
1 % CV Intra-day
2 % CV
NAD 9.9 7.2 7.7 4.2
NADP 9.3 7.7 7.1 3.4
2-PYR 16 32 45 13
1 - M N 3 41 98 54 0
1 Measurements from the same time point on d 1–4 were used to calculate the inter-
day percent CV.
2 Intra-day percent CV was calculated using the 4 measurements taken on d 4.
Biochemical assessment of pellagra 2015
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 There was also no correlation between total metabolite excretion
and the NAD:NADP ratio when using creatinine- or osmolality-
adjusted metabolite concentrations. In this sample, the use of
osmolalityhad no apparent advantages over creatinine for adjust-
ing niacin metabolite concentrations.
Discussion
The most prominent ﬁnding of this work was that the ratio of
whole blood NAD and NADP concentrations were not signif-
icantly depressed in clinical pellagra, despite the inter- and intra-day
stability of the ratio and the individual metabolite concentrations
in 2 healthy volunteers. This counter-intuitive ﬁnding contrasts
with results from dietary depletion studies (16) but agrees with
earlier work on pellagra patients (19–21). In contrast to the un-
responsive nature of NAD and NADP, low excretion of urinary
niacin metabolites was shown to be a sensitive and speciﬁc indi-
cator of clinical pellagra in this study population.
Microtiter plate-based enzyme cycling assays were selected
for the analysis of NAD and NADP because of the small sample
volumes required and their suitability for analyzing large num-
bers of samples. Base and acid were used to extract total NAD,
NADH, NADP, and NADPH. The extracts were stored at 280 C
prior to analysis and were reportedly stable at 220 C for .2y
(18). During analysis of the extract, NAD
1 and NADP
1 were
used for the oxidation of ethanol and isocitrate by the enzymes
alcohol dehydrogenase and isocitric dehydrogenase, respectively.
The reactions produced NADH and NADPH, which were reoxi-
dized by reduction of the dye thiazolyl blue tetrazolium bromide
via the electron transport reagent phenazine ethosulfate. Re-
duction of thiazolyl blue tetrazolium bromide converted it from
an initial yellow color to a blue formazan. The amount of blue
formazan produced was dependent on the quantity of NAD and
NADP present and was quantiﬁed by absorption measurement
at 570 nm.
The assays had low limits of detection and quantiﬁcation
and these were less than the lower limits (;3500 nmol/L for
NAD and NADP) previously seen in study subjects consuming a
niacin-deﬁcient diet (16). The upper limits for the assays were
sufﬁcient to measure the majority of NAD and NADP concen-
trations, likely to be found in population samples, without fur-
ther dilution. Stability studies (see online supporting material)
showed venous whole blood samples to be most stable when
frozen; however, if thawed, cell lysis resulted in a slow decrease
in NADP and rapid loss of NAD. The samples were relatively
stable for a period of 7.5 h (the longest time that samples would
normally spend ‘‘in the ﬁeld’’ during a survey) in an unfrozen
state between 5.5 and 37 C. Consequently, samples were main-
tained at 4–8 C in cool packs during collection and not frozen.
Finger prick blood sampling was considered as an alternative to
venous sampling and has been used under laboratory conditions
(24). However, from our experience in ﬁeld surveys, hemolysis
was more likely to occur and this would have lead to NAD and
NADP depletion.
To investigate whether status changed with collection time,
paired peripheral whole blood and urine samples were collected
from 2 subjects over 4 consecutive days. Concentrations of whole
blood NAD and NADP (Fig. 1) were similar to those found by
other workers (24–26) and showed less change than the urinary
niacin metabolite concentrations (Table 1). The greater variation
in the urinary metabolite concentrations resulted from recent
dietary intake (15). We concluded that whole blood NAD and
NADP concentrations would give the most stable measurement
of status, because they varied least with collection time.
In pellagra patients, the excretion of urinary metabolites,
relative to creatinine, declined sharply, whereas the NAD:NADP
ratio did not change. Only 4 of 11 cases identiﬁed using clinical
signs had a niacin index ,100. In treated patients, there was a
dramatic increase in the concentration of urinary metabolites
but little change in the whole blood NAD:NADP ratio. This lack
of change in the NAD:NADP ratio contrasts with that in die-
tary depletion studies (16) and remains an enigma in need of
TABLE 2 Whole blood NAD and NADP and urinary metabolite concentrations in community controls
and newly admitted and treated pellagra patients
1
Community controls New admissions Treated patients P
n 107 11 23
Whole blood
NAD, mmol/L 24.3
b (23.0, 25.6) 29.7
a (22.4, 37.0) 29.1
a (25.0, 33.2) 0.005
NADP, mmol/L 19.6
b (18.3, 20.8) 26.1
a (21.3, 30.9) 24.4
a (21.5, 27.4) ,0.001
Adjusted NAD, mmol/L 25.4 (24.3, 26.5) 26.5 (17.9, 35.2) 26.4 (23.1, 29.7) 0.747
Adjusted NADP, mmol/L 20.5 (19.5, 21.4) 23.5 (18.3, 28.7) 22.1 (20.0, 24.3) 0.087
Niacin index 126 (121, 130) 114 (95, 134) 120 (109, 131) 0.222
Urine
1-MN,
2 mg/g creatinine 3.1
b (2.6, 3.5) 1.2
c (0.3, 2.1) 45.3
a (14.3, 76.2) ,0.001
2-PYR,
3 mg/g creatinine 7.6
b (6.3, 8.9) 2.4
c (1.0, 3.7) 55.2
a (21.8, 88.7) ,0.001
1 Values are means (95% CI). Means in a row with superscripts without a common letter differ, P , 0.05.
2 To convert 1-MN from mg/g creatinine to mmol/mmol creatinine, multiply by 0.825.
3 To convert 2-PYR from mg/g creatinine to mmol/mmol creatinine, multiply by 0.743.
TABLE 3 Sensitivity and speciﬁcity of biochemical measures
in the detection of clinical pellagra
1
Measure Sensitivity
2 Specificity
3
Positive
predictive value
4
%
Low urine metabolites 90.9 (57.1, 99.5) 71.6 (61.3, 80.1) 27.0 (14.4, 44.4)
2-PYR ,4 mg/g creatinine 81.8 (47.8, 96.8) 75.8 (65.7, 83.7) 28.1 (14.4, 47.0)
1-MN ,1.6 mg/g creatinine 81.8 (47.8, 96.8) 78.9 (69.1, 86.4) 31.0 (16.0, 51.0)
Niacin index ,100 36.4 (12.4, 68.4) 88.4 (79.8, 93.8) 26.7 (8.9, 55.2)
1 Values are percentages (95% CI).
2 Sensitivity is the probability of a subject having a positive biochemical test result for
pellagra if exhibiting clinical signs.
3 Speciﬁcity is the probability of having a negative biochemical test if not exhibiting
clinical signs.
4 The positive predictive value is the probability of a subject having clinical signs for
pellagra if they had a positive biochemical test.
2016 Creeke et al.
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 explanation. It is likely that a number of factors are operating.
One possibility is that erythrocytes are not subject to as much
oxidative stress as sun-exposed skin. NAD concentrations as a
result do not fall as quickly and can be maintained by the avail-
able niacin, even while dermatitis is developing. Another possi-
bility is that there are genetic factors in the survey population
that allow NAD concentrations in some cell types (such as eryth-
rocytes) to be maintained at the expense of others (such as the
skin) during periods of niacin deﬁciency.
The control group used in this study consisted of women
from the local area, ;29% of whom had low niacin metabolite
excretion (22). Further work is recommended to obtain a ref-
erence dataset from populations where niacin deﬁciency is rare.
We conclude, from the data currently available, that the
NAD:NADP ratio cannot be used to diagnose clinical pellagra
and would lead to erroneously low estimates of niacin deﬁciency
if used in population surveys. Quantiﬁcation of the urinary me-
tabolites remains the method of choice for determining the epi-
demiology of niacin deﬁciency.
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